BACKGROUND: Octreotide LAR is an established treatment for malignant carcinoid syndrome. However, studies with large number of patients and long follow-up are lacking. AIM: To present long-terms results with octreotide LAR, assessing duration of clinical and objective response and treatment tolerance, in a large, homogeneous cohort of patients with malignant carcinoid syndrome. METHODS: A total of 108 patients with metastatic midgut neuroendocrine tumours were included in this 8-year study. Clinical evaluation was based on a symptom score. Radiological assessment was based on RECIST (Response Evaluation Criteria In Solid Tumours) criteria. RESULTS: Of the 108 patients, 24% had a sustained symptomatic response. In the remaining patients, loss of symptomatic response with the initial dose was noted within 3-60 months. In 17% of them, symptoms were controlled by just an increase of octreotide LAR dose, whilst the other patients required additional treatment. Overall, in 45.3% of patients, symptoms were well controlled during the study period with only octreotide LAR, and no additional treatment was required. No significant adverse effects were noted. CONCLUSIONS: Octreotide LAR treatment provides a sustained symptomatic response in about half of the patients with malignant carcinoid syndrome and contributes to disease stabilization for a longer period than previously described.
BACKGROUND:OctreotideLAR is an established treatment for malignant carcinoid syndrome. However, studies with large number of patients and long follow-up are lacking. AIM: To present long-terms results with octreotideLAR, assessing duration of clinical and objective response and treatment tolerance, in a large, homogeneous cohort of patients with malignant carcinoid syndrome. METHODS: A total of 108 patients with metastatic midgut neuroendocrine tumours were included in this 8-year study. Clinical evaluation was based on a symptom score. Radiological assessment was based on RECIST (Response Evaluation Criteria In Solid Tumours) criteria. RESULTS: Of the 108 patients, 24% had a sustained symptomatic response. In the remaining patients, loss of symptomatic response with the initial dose was noted within 3-60 months. In 17% of them, symptoms were controlled by just an increase of octreotideLAR dose, whilst the other patients required additional treatment. Overall, in 45.3% of patients, symptoms were well controlled during the study period with only octreotideLAR, and no additional treatment was required. No significant adverse effects were noted. CONCLUSIONS:OctreotideLAR treatment provides a sustained symptomatic response in about half of the patients with malignant carcinoid syndrome and contributes to disease stabilization for a longer period than previously described.
Authors: Jonathan R Strosberg; Thorvardur R Halfdanarson; Andrew M Bellizzi; Jennifer A Chan; Joseph S Dillon; Anthony P Heaney; Pamela L Kunz; Thomas M O'Dorisio; Riad Salem; Eva Segelov; James R Howe; Rodney F Pommier; Kari Brendtro; Mohammad A Bashir; Simron Singh; Michael C Soulen; Laura Tang; Jerome S Zacks; James C Yao; Emily K Bergsland Journal: Pancreas Date: 2017-07 Impact factor: 3.327
Authors: Mohammed B Allaw; Jeffrey M Switchenko; Lana Khalil; Christina Wu; Olatunji B Alese; Mehmet Akce; Amber Draper; Aaron T Jones; Bassel El-Rayes; Walid Shaib Journal: Oncology Date: 2022-01-25 Impact factor: 3.734
Authors: John K Ramage; A Ahmed; J Ardill; N Bax; D J Breen; M E Caplin; P Corrie; J Davar; A H Davies; V Lewington; T Meyer; J Newell-Price; G Poston; N Reed; A Rockall; W Steward; R V Thakker; C Toubanakis; J Valle; C Verbeke; A B Grossman Journal: Gut Date: 2011-11-03 Impact factor: 23.059